Riptide Bioscience Inc.

Riptide Bioscience Inc. is a biopharmaceutical company that develops engineered peptide therapeutics based on Host Defense Peptides (HDPs). By identifying the key structures of these naturally occurring proteins, the company uses proprietary methods to design synthetic peptides with significantly enhanced efficacy. These engineered peptides act through electrostatic attraction to microbial cell surfaces, allowing them to combat infections by penetrating bacterial biofilms that often resist conventional antibiotics. Additionally, the company has developed peptides designed to modulate inflammatory processes and target tumor-associated macrophages within the tumor microenvironment to inhibit tumor growth and metastasis.

These therapeutic candidates are intended to address significant medical challenges, including antibiotic-resistant infections, chronic inflammatory conditions, and various solid organ cancers. The company’s approach is supported by preclinical data from animal models and independent research, including collaborations with academic institutions and grants from organizations such as the National Cancer Institute, the National Eye Institute, and the Department of Defense. Riptide focuses on developing drug candidates for topical, subcutaneous, or other administrative applications in areas such as wound healing, pulmonary fibrosis, and oncology, while actively seeking pharmaceutical partnerships to advance its proprietary pipeline.